Stock comparison
ResMed
Waters
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
RMD
ResMed
Market cap
$29.57B
Sector
Healthcare
WAT
Waters
Market cap
$22.69B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | RMD | WAT | Winner |
|---|---|---|---|
| Warren Buffett | 64C | 57C | RMD |
| Benjamin Graham | 67B | 56C | RMD |
| Philip Fisher | 67B | 54C | RMD |
| Peter Lynch | 50C | 15F | RMD |
| Joel Greenblatt | 39D | 42D | WAT |
| Charlie Munger | 61C | 59C | RMD |
| Terry Smith | 65B | 53C | RMD |
Side-by-side metrics
| Metric | RMD | WAT |
|---|---|---|
| Market cap | $29.57B | $22.69B |
| P/E (TTM) | 19.6x | 63.6x |
| EV/EBIT | 17.1x | 30.7x |
| ROIC (TTM) | 19.63% | 2.25% |
| Gross margin | 61.69% | 55.02% |
| Net margin | 27.44% | 11.91% |
| Revenue CAGR 5y | 12.64% | 3.24% |
| EPS CAGR 5y | 30.73% | -1.02% |
| Debt / Equity | 0.1x | 0.3x |
| Dividend yield | 1.14% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
RMD leads on
- EPS CAGR 5y30.73%vs -1.02%+103%
- Dividend yield1.14%vs 0.0%+100%
- ROIC (TTM)19.63%vs 2.25%+89%
- Revenue CAGR 5y12.64%vs 3.24%+74%
WAT leads on
No clear edges - the other side wins or ties on every measured metric.
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.